Dicerna Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases, announced the pricing of its initial public offering of 6 million shares of common stock at $15.00 per share, before underwriting discounts. The offering is expected to close on February 4, 2014.
In an amended S-1 filing with the U.S. Securities and Exchange Commission, the company recently expected to price the initial public offering of 6 million common shares at $14 per share.
In addition, Dicerna has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock from Dicerna at the public offering price, before underwriting discounts.
The Watertown, Massachusetts-based company shares to begin trading on the NASDAQ Global Select Market under the ticker symbol "DRNA" on January 30, 2014.
Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated is acting as co-lead manager for the offering.
Showing posts with label Dicerna Pharma. Show all posts
Showing posts with label Dicerna Pharma. Show all posts
Thursday, January 30, 2014
Subscribe to:
Posts (Atom)